RxDoctor Payments Data

Sherry Rivera

Family · Petal, MSNPI 1982188421

Payments from drug & device makers

$2,202in general payments, 2019–2025

Across 100 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$367
  • Lilly USA, LLC$281
  • Merck$226
  • Astellas Pharma US Inc$176
  • Novo Nordisk$155
  • Pfizer$150
  • plus $846 from 16 others

What the payments were for

  • Food & beverage$2,202100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,202 in reported general payments places this provider in the 80th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$42,315
Medicare patients
298
Services billed
804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide15$13,130
JardianceEmpagliflozin15$11,157
FarxigaDapagliflozin Propanediol11$5,528
Nebivolol Hcl29$1,598
Amlodipine-ValsartanAmlodipine Besylate/Valsartan24$1,072
Valsartan27$839
Duloxetine Hcl74$768
Gabapentin47$616
Potassium Chloride42$594
Carvedilol96$576
Nifedipine ErNifedipine21$506
Atorvastatin Calcium64$450
Omeprazole31$445
Doxazosin Mesylate23$438
Irbesartan37$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$138$13,13015 claims
Boehringer IngelheimJardiance$134$11,15715 claims
AstraZenecaFarxiga$367$5,52811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,007 family providers in Mississippi.

Other family in Petal

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →